AstraZeneca entered an agreement with Sun Pharmaceutical Industries for the distribution of Sodium Zirconium Cyclosilicate (SZC) powder for oral suspension in India. Under the agreement, both companies will promote, market and distribute SZC in India. AstraZeneca will market SZC as Lokelma whereas Sun Pharma will promote and distribute the therapy as Gimliand.